Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

MedX Health Launches SkinSecure(TM) to Bring Direct, Non-Invasive, Objective Biological Measurement to Skin Health Research

MedX Health Launches SkinSecure SaaS to Target CRO Market, But Liquidity Crisis and Going Concern Risks Dominate

By The Northwire Desk — AI Analysis Jun 25, 2026 · 23:52 MDX · 0.055 Medx Health Corp.
Executive Summary
  • MedX Health Corp. announced the commercial launch of SkinSecure™, a cloud-based SaaS platform that integrates with its proprietary SIAscope imaging devices.
  • The platform delivers non-invasive, quantitative mapping of collagen, melanin, and hemoglobin for clinical research workflows.
  • It is designed to replace expensive, invasive punch biopsies in clinical trials, offering immediate objective biomarker data across multiple sites.
  • Full commercial deployment is scheduled for July 2026, targeting dermatology trials, aesthetic studies, and pharmaceutical development.
  • The technology is intended for investigational use only and is not approved for diagnostic or routine clinical care.
  • The core SIAscopy technology has already been utilized by over 29 CROs and sponsors globally.
Material Impact
  • The launch represents a commercialization milestone for MedX's existing SIAscopy/DermSecure ecosystem, but it does not fundamentally alter the company's financial trajectory or risk profile.
  • The addressable market (clinical research CROs) is niche, and sales cycles in this sector are historically long and capital-intensive.
  • The stock has traded in a tight $0.05–$0.06 range for over a year, indicating the market has already priced in the incremental nature of this rollout.
  • The announcement does not address the company's severe liquidity constraints, negative working capital, or going concern status. It is a follow-up to prior development milestones and financing rounds.
MDX · Price
Company Overview
  • MedX Health Corp. operates in the medical device and digital health space, focusing on non-invasive skin health measurement and photobiomodulation therapies.
  • Core assets include the DermSecure® telemedicine platform and SIAscopy® imaging technology, which capture biological data (collagen, melanin, hemoglobin) without biopsies.
  • The company also operates a photobiomodulation division producing laser devices for veterinary (LumaVet) and dental (Oralase) applications.
  • Strategic focus is shifting toward SaaS-based clinical research tools and occupational health markets, leveraging an expanding database of ~85,000 clinically reviewed skin images.
Read the original news release →

More from Medx Health Corp.

May 15, 2026 · 19:40

MedX Secures Runway with Debt Refinancing Amidst Dilution Concerns and Modest Cash Injection

Financings Mar 16, 2026 · 07:00

MedX Announces Application for Extension of Non-Brokered Private Placement

Financings Feb 27, 2026 · 11:44

MedX Health closes $2.7-million private placement

Financings Feb 27, 2026 · 07:00

MedX Announces $2,700,000 Initial Closing of Non-Brokered Private Placement of Series IV Convertible Loan Notes

Financings Feb 02, 2026 · 21:05

MedX Health arranges $5-million note financing

Financings Feb 02, 2026 · 17:01

MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes

Financings